Reported Cases of Serotonin Syndrome in MDMA Users in FAERS Database

Introduction

Corkery and colleagues situate their work in the context of expanding clinical interest in 3,4-methylenedioxymethamphetamine (MDMA) as an investigational treatment for PTSD and other anxiety-related disorders. They note that MDMA produces psychoactive effects via multiple actions on monoamine neurotransmission, including release and reuptake inhibition of serotonin, dopamine and norepinephrine, and that proposed therapeutic mechanisms include facilitation of emotional processing and interpersonal connectedness. Adverse events reported in controlled trials have been generally transient (for example, hypertension, muscle tension and nausea), but because MDMA affects serotonergic signalling there is a theoretical risk of serotonin syndrome (SS), a potentially life-threatening condition characterised by neuromuscular, autonomic and cognitive symptoms when serotonergic activity is excessive. The study sets out to examine whether cases of SS attributed to MDMA have been reported in the FDA Adverse Event Reporting System (FAERS). Specifically, the investigators sought to identify FAERS reports listing MDMA together with SS, to determine whether any SS cases listed MDMA as the sole compound, and to characterise concomitant substances—particularly other serotonergic agents—that might have contributed to SS risk. This work aims to place the safety profile observed in controlled clinical trials in the broader context of spontaneous surveillance data from real-world use.